Peptide profile
Ziconotide
Also known as SNX-111
N-type calcium channel antagonist
Approved medicines exist
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
Prialt has an FDA-approved indication for severe chronic pain in selected patients receiving intrathecal therapy. This specialized use does not establish a wellness or cognition benefit.
View the supporting source- Research area
- Neuroscience
- Biological target or mechanism
- N-type calcium channel antagonist
- Evidence context
- Approved medicines exist
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
